Intercept Pharmaceuticals (ICPT) and Xencor (XNCR) Head-To-Head Survey

Intercept Pharmaceuticals (NASDAQ: ICPT) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Valuation & Earnings

This table compares Intercept Pharmaceuticals and Xencor’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intercept Pharmaceuticals $24.95 million 59.62 -$412.83 million ($14.80) -4.00
Xencor $87.52 million 11.91 $23.62 million ($1.00) -22.19

Xencor has higher revenue and earnings than Intercept Pharmaceuticals. Xencor is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

73.8% of Intercept Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.6% of Xencor shares are owned by institutional investors. 4.5% of Intercept Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Intercept Pharmaceuticals and Xencor, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intercept Pharmaceuticals 2 9 9 0 2.35
Xencor 0 2 4 0 2.67

Intercept Pharmaceuticals presently has a consensus target price of $143.21, indicating a potential upside of 141.66%. Xencor has a consensus target price of $30.80, indicating a potential upside of 38.80%. Given Intercept Pharmaceuticals’ higher probable upside, equities research analysts plainly believe Intercept Pharmaceuticals is more favorable than Xencor.

Profitability

This table compares Intercept Pharmaceuticals and Xencor’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intercept Pharmaceuticals -344.74% -176.51% -57.15%
Xencor -148.29% -15.26% -11.11%

Volatility & Risk

Intercept Pharmaceuticals has a beta of -2.08, suggesting that its stock price is 308% less volatile than the S&P 500. Comparatively, Xencor has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Summary

Xencor beats Intercept Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Xencor Company Profile

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply